Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study

被引：0

作者：

Moreau, P. ^{[1
]}

Facon, T. ^{[2
]}

Usmani, S. Z. ^{[3
]}

Bahlis, N. ^{[4
]}

Raje, N. ^{[5
]}

Plesner, T. ^{[6
,7
]}

Orlowski, R. Z. ^{[8
]}

Basu, S. ^{[9
,10
]}

Nahi, H. ^{[11
]}

Hulin, C. ^{[12
]}

Quach, H. ^{[13
]}

Goldschmidt, H. ^{[14
,15
]}

O'Dwyer, M. ^{[16
]}

Perrot, A. ^{[17
]}

Venner, C. P. ^{[18
,19
]}

Weisel, K. ^{[20
]}

Tiab, M. ^{[21
]}

Macro, M. ^{[22
]}

Frenzel, L. ^{[23
]}

Leleu, X. ^{[24
]}

Pei, H. ^{[25
]}

Krevvata, M. ^{[26
]}

Carson, R. ^{[26
]}

Borgsten, F. ^{[27
]}

Kumar, S. K. ^{[28
]}

机构：

[1] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[5] Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, Boston, MA 02114 USA

[6] Vejle Hosp, Vejle, Denmark

[7] Univ Southern Denmark, Vejle, Denmark

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[9] Royal Wolverhampton NHS Trust, Wolverhampton, England

[10] Univ Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, England

[11] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[12] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[13] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[14] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[15] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[16] NUI, Dept Med Haematol, Galway, Ireland

[17] Univ Toulouse, UPS, CHU Toulouse, IUCT O,Serv Hematol, Toulouse, France

[18] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[19] BC Canc Vancouver Ctr Grp, Vancouver, BC, Canada

[20] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[21] CHD Vendee, La Roche Sur Yon, France

[22] Ctr Hosp Univ CHU Caen, Caen, France

[23] Hop Necker Enfants Malad, Paris, France

[24] CHU Poitiers, Hop Mil, Poitiers, France

[25] Janssen Res & Dev LLC, Titusville, NJ USA

[26] Janssen Res & Dev LLC, Spring House, PA USA

[27] Janssen Res & Dev LLC, Raritan, NJ USA

[28] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1110

引用

页码：316 / 317

页数：2

共 50 条

[11] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[12] Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Christopher
Venner, P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Borgsten, Fredrik
Usmani, Saad Zafar
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[13] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
[J]. LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[14] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
[J]. Leukemia, 2022, 36 : 1066 - 1077
[15] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
[J]. BLOOD, 2022, 140 : 10133 - 10136
[16] Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.
Perrot, Aurore
Facon, Thierry
Plesner, Torben
Usmani, Saad Zafar
Kumar, Shaji
Bahlis, Nizar J.
Ramasamy, Karthik
Roussel, Murielle
Araujo, Carla
Jaccard, Arnaud
Delforge, Michel
McKay, Caroline
Gries, Katharine
Trudeau, Jeremiah
Hulin, Cyrille
Weisel, Katja
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[17] Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant
Gries, Katharine
Facon, Thierry
Plesner, Torben
Usmani, Saad
Kumar, Shaji
Orlowski, Robert Z.
Bahlis, Nizar J.
Nahi, Hareth
Mollee, Peter
Ramasamy, Karthik
Roussel, Murielle
Delforge, Michel
Karlin, Lionel
Arnulf, Bertrand
Chari, Ajai
Hulin, Cyrille
Weisel, Katja
He, Jianming
Ho, Kai Fai
Wang, Jim
Van Rampelbergh, Rian
Uhlar, Clarissa
Kobos, Rachel
Perrot, Aurore
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E225 - E226
[18] Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, Thierry
Moreau, Philippe
Weisel, Katja
Goldschmidt, Hartmut
Usmani, Saad Z.
Chari, Ajai
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Jacquet, Caroline
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Cook, Gordon
Wang, George
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
[J]. LEUKEMIA, 2025, : 942 - 950
[19] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Leleu, Xavier P.
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Chretien, Marie-Lorraine
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[20] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Usmani, Saad Z.
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Perrot, Aurore
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Van Rampelbergh, Rian
Tromp, Brenda
Delioukina, Maria
Facon, Thierry
[J]. BLOOD, 2021, 138

← 1 2 3 4 5 →